Immuno-oncology

Show results for

Unknown (2208)
Models (125)
Genomics (113)
Transcriptomics (41)
Proteomics (14)
Clinical (11)
Other (5)
Metabolomics (2)

Organisms

Homo sapiens (111)
Mus musculus (35)
Schizophyllum commune H4-8 (9)
Mycobacterium tuberculosis SP7 (9)
Salmonella enterica subsp. enterica serovar Typhimurium str. T000240 (9)
Oryza sativa Japonica Group (9)
Rabbit calicivirus (9)
Crotalus durissus terrificus (9)
Eriocheir sinensis (9)
Candidatus Endoriftia persephonae (9)
Mycobacterium tuberculosis SP10 (9)
Mycobacterium tuberculosis SP13 (9)
Cotesia typhae (9)
Mycobacterium tuberculosis SP22 (9)
Cepaea nemoralis (9)
Enterobacter ludwigii (9)
Trichoderma asperellum CBS 433.97 (9)
Corynebacterium diphtheriae bv. mitis str. ISS 3319 (9)
Nakaseomyces glabratus (9)
Olea europaea (9)
Chlamydomonas reinhardtii (9)
Lama (9)
Planorbella pilsbryi (9)
Wolbachia sp. wMelPop (9)
Pyricularia oryzae P131 (9)
Canis lupus familiaris (3)
Vesicular stomatitis virus (2)
Cancer (1)
Mycobacterium tuberculosis variant bovis BCG (1)
synthetic construct (1)

Organisms

Homo sapiens (48)
Mus musculus (40)
Canis lupus familiaris (5)
Macaca mulatta (1)

Repository

BioModels (125)
ENA (108)
geo (50)
pride (9)
MassIVE (3)
MetaboLights (2)
biostudies-arrayexpress (1)
EGA (1)
PanoramaPublic (1)

Tissue

Cell culture (5)
Epithelial cell (2)
T cell (2)
Skin (1)
Lymph node (1)
Blood plasma (1)
Lung (1)
Permanent cell line cell (1)

Disease

Cancer (10)
Colorectal Neoplasms (4)
Breast cancer (3)
Melanoma (2)
Leukemia (2)
Lymphoma (2)
Lymphoid leukemia (2)
Carcinoma (2)
Neoplasms (2)
Colon cancer (2)
Skin cancer (1)
Non-Hodgkin lymphoma (1)
Urinary bladder cancer (1)
Glioblastoma multiforme (1)
Leukemia, Myeloid (1)
Carcinoma, Renal Cell (1)
Pancreatic Neoplasms (1)
Multiple myeloma (1)
Lung cancer (1)
Cervix carcinoma (1)
Kidney cancer (1)
Acute leukemia (1)

Technology Type

Mass Spectrometry (9)
Shotgun proteomics (6)
Mass spectrometry (2)
Olink affinity proteomics (1)
Affinity proteomics (1)
SRM/MRM (1)
Data-dependent acquisition (1)

Instrument Platform

Liquid Chromatography MS - positive - reverse phase (2)
Illumina HiSeq 4000 (1)
ThermoFisher Orbitrap (1)
QExactive LCMS (1)
UltrafleXtreme (1)
Q Exactive HF (1)
Liquid Chromatography MS - negative - reverse phase (1)

Publication Date

2024 (115)
2019 (16)
2020 (15)
2026 (11)
2022 (9)
2025 (9)
2023 (9)
2021 (3)
2016 (2)
2018 (2)

UNIPROT ID/AC

P60568 (5)
P01137 (4)
Q0GK43 (2)
C4NUM1 (2)
Q3UNK5 (1)
P70293 (1)
S5S2F2 (1)
Q14609 (1)
A2RSY7 (1)
Q15116 (1)
P16410 (1)
Q8WXI7 (1)
Q9ES17 (1)
P01579 (1)
P08887 (1)
P05231 (1)
P13232 (1)

CHEBI ID

CHEBI:144829 (10)
CHEBI:4027 (1)
CHEBI:28748 (1)
CHEBI:17234 (1)
CHEBI:137604 (1)
CHEBI:134487 (1)
CHEBI:134451 (1)
CHEBI:65294 (1)
CHEBI:66862 (1)
CHEBI:85851 (1)
CHEBI:65302 (1)
CHEBI:66848 (1)
CHEBI:134270 (1)
CHEBI:134271 (1)
CHEBI:64431 (1)
CHEBI:64519 (1)
CHEBI:64525 (1)
CHEBI:64526 (1)
CHEBI:64446 (1)
CHEBI:64504 (1)
CHEBI:64523 (1)
CHEBI:64433 (1)
CHEBI:66857 (1)
CHEBI:85766 (1)
CHEBI:64516 (1)
CHEBI:64517 (1)
CHEBI:86472 (1)
CHEBI:66849 (1)
CHEBI:66850 (1)
CHEBI:65303 (1)

Metabolite Name

Phosphatidylethanolamine(38:4) (1)
Phosphatidylethanolamine(36:4) (1)
Phosphatidylethanolamine(36:1) (1)
Phosphatidylcholine(40:8) (1)
Phosphatidylcholine(40:4) (1)
Phosphatidylcholine(38:6) (1)
Phosphatidylcholine(38:5) (1)
Phosphatidylcholine(36:3) (1)
Phosphatidylcholine(36:2) (1)
Phosphatidylcholine(35:2) (1)
Phosphatidylcholine(34:1) (1)
Phosphatidylcholine(34:2) (1)
Phosphatidylcholine(33:5) (1)
Phosphatidylcholine(32:2) (1)
Phosphatidylcholine(32:0) (1)
Phosphatidylcholine(31:0) (1)
Phosphatidylcholine(33:1) (1)
Phosphatidylcholine(30:0) (1)
Phosphatidylcholine(28:0) (1)
Phosphatidylcholine(40:6) (1)
Phosphatidylcholine(38:3) (1)
Phosphatidylcholine(38:4) (1)
Phosphatidylcholine(36:1) (1)
Phosphatidylcholine(36:5) (1)
Phosphatidylcholine(32:1) (1)
Phosphatidylcholine(30:1) (1)

First Public Date

2024 (24)
2023 (19)
2026 (18)
2025 (17)
2022 (11)
2020 (8)
2021 (4)
2019 (3)
2017 (3)
2016 (1)

Modelling Approach

Ordinary differential equation model (118)

Study status

Recruiting (6)
Active, not recruiting (2)
Completed (2)
Withdrawn (1)

Lab affiliation

Structural Genomics Consortium (SGC), Chemical biology Group, University of Oxford, United Kingdom. also affiliated with: Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, United Kingdom. (1)
Department of Cellular and Molecular Pharmacology, University of California, San Francisco (1)
Metastasis Research Laboratory Liège université GIGA institute ULIEGE-CHU-B23 +4, 4000 Liège Belgium (1)
Regeneron Pharmaceuticals (1)
Oncology Research and Development, Pfizer Inc. (1)
Departments of Pediatrics and Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte CA 91010 (1)
Central Institute for Translational Cancer Research (TranslaTUM) Radiation Immuno-Oncology Group, Klinikum rechts der Isar (1)
Icahn School of Medicine at Mount Sinai (1)
Weizmann Institute of Science (1)

Keyword

Pembrolizumab (6)
Immuno-oncology (4)
Immuno-Oncology (3)
Immunotherapy (3)
Checkpoint inhibitor (2)
Immune Checkpoint Inhibitors (2)
Oncology (2)
Nivolumab (2)
Prostaglandin E2 (PGE2) (1)
CR6086 (1)
Anti PD-1 (1)
Checkpoint Inhibitors (1)
Programmed cell death protein-1 (PD-1) inhibitor (1)
Programmed death ligand 1 (PD-L1) inhibitor (1)
MEL (1)
Arginase (1)
Arginase Inhibitor (1)
INCB001158 (CB-1158) (1)
GEJ (1)
Immune Therapy (1)
Immune checkpoint inhibitors (1)
EP4 antagonist (1)
Tumor Metabolism (1)
Balstilimab (1)
Peptide vaccine (1)
WT1-expressing tumors (1)
Galinpepimut-S (1)
PD1 inhibitor (1)
Combination immunotherapy (1)
Heteroclitic (1)

IsPrivate

False (125)

Submitter Keywords

Immuno-oncology (124)

Modification

Not available (1)

Study type

Interventional (10)
RNA-seq of coding RNA (1)
Observational (1)

Release Date

2023 (365)
2022 (356)
2024 (313)
2021 (287)
2025 (278)
2020 (201)
2019 (140)
2018 (98)
2017 (53)
2026 (38)
2016 (33)
2015 (20)
2014 (11)
2012 (6)
2013 (5)
2011 (1)
2010 (1)
2008 (1)
2006 (1)
2004 (1)

Location

United States (8)
France (3)
Italy (3)
Spain (3)
United Kingdom (2)
New Zealand (1)
Poland (1)
Germany (1)
Israel (1)
Belgium (1)
Netherlands (1)
Australia (1)
Austria (1)
Switzerland (1)

Previous page
1 / 252
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 252
Next page

Sort by:

Relevance

Page size

Longitudinal Olink affinity proteomics profiling of cytokine release syndrome in myeloma patients receiving BCMA-directed CAR-T therapy

This submission contains de-identified Olink NPX affinity proteomics data from longitudinal peripheral blood samples collected from patients with relapsed/refractory multiple myeloma treated with BCMA-directed CAR-T therapy (ide-cel or cilta-cel) in a prospective single-center pilot study. Samples w...

ORGANISM(S): Homo sapiens (Human)

2026-04-28 | PAD000041 | Pride